ArticleMolecules (Basel, Switzerland)2019
New Quinoline-Based Heterocycles as Anticancer Agents Targeting Bcl-2.
Article in Molecules (Basel, Switzerland), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 53 citations in OpenAlex.
- Ultrasound-mediated Tandem Synthesis of New Highly Functionalized 4-Hydroxy-quinoline Derivatives with Amidine and Imidate Skeletons from Trichloroacet-amidine(imidate), Alkynes, and Isatoic Anhydride.Current organic synthesis · 2026Article
- Quinoline and coumarin isoxazole derivatives: synthesis, antitumor evaluation and molecular docking studies with Bcl-2.RSC advances · 2025Article
- Efficacy of graphene quantum dot-hyaluronic acid nanocomposites containing quinoline for target therapy against cancer cells.Scientific reports · 2025Article
- Quinolines: A Promising Heterocyclic Scaffold for Cancer Therapeutics.Current medicinal chemistry · 2025Review
- Design and synthesis of novel 2-(2-(4-bromophenyl)quinolin-4-yl)-1,3,4-oxadiazole derivatives as anticancer and antimicrobial candidates:RSC advances · 2024Article
- New multifunctional hybrids as modulators of apoptosis markers and topoisomerase II in breast cancer therapy: synthesis, characterization, andRSC advances · 2024Article
- Design, synthesis, and antiproliferative screening of new quinoline derivatives bearing aRSC advances · 2024Article
- Harnessing molecular hybridization approach to discover novel quinoline EGFR-TK inhibitors for cancer treatment.Future medicinal chemistry · 2024Article
- Design, Synthesis, and Potent Anticancer Activity of Novel Indole-Based Bcl-2 Inhibitors.International journal of molecular sciences · 2023Article
- Article
- Investigation of the mechanism of action of mefloquine and derivatives against the parasite Echinococcus multilocularis.International journal for parasitology. Drugs and drug resistance · 2023Article
- Nitrogen Containing Heterocycles as Anticancer Agents: A Medicinal Chemistry Perspective.Pharmaceuticals (Basel, Switzerland) · 2023Review
- Uracil as a Zn-Binding Bioisostere of the Allergic Benzenesulfonamide in the Design of Quinoline-Uracil Hybrids as Anticancer Carbonic Anhydrase Inhibitors.Pharmaceuticals (Basel, Switzerland) · 2022Article
- New Bioactive Fused Triazolothiadiazoles as Bcl-2-Targeted Anticancer Agents.International journal of molecular sciences · 2021Article
- Facile synthesis andHeliyon · 2021Article
- Design, Synthesis and Evaluation of New Bioactive Oxadiazole Derivatives as Anticancer Agents Targeting Bcl-2.International journal of molecular sciences · 2020Article
- Molecular targets and anticancer activity of quinoline-chalcone hybrids: literature review.RSC advances · 2020Review
- Essential Oil-Based Design and Development of Novel Anti-Molecules (Basel, Switzerland) · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 4 institutions in 3 countries.
Funding
Abstract
The Bcl-2 protein has been studied as an anticancer drug target in recent years, due to its gatekeeper role in resisting programmed cancer cell death (apoptosis), and the design of BH3 domain mimetics has led to the clinical approval of Venetoclax (ABT-199) for the treatment of chronic lymphocytic leukaemia. In this work we extend our previous studies on the discovery of indole-based heterocycles as Bcl-2 inhibitors, to the identification of quinolin-4-yl based oxadiazole and triazole analogues. Target compounds were readily synthesized via a common aryl-substituted quinolin-4-carbonyl-
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.